Cargando…

Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats

BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohdich, Nadja, Zschiesche, Eva, Wolf, Oliver, Loehlein, Wolfgang, Pobel, Thierry, Gil, Maria José, Roepke, Rainer K. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240940/
https://www.ncbi.nlm.nih.gov/pubmed/30454052
http://dx.doi.org/10.1186/s13071-018-3175-z
_version_ 1783371714370994176
author Rohdich, Nadja
Zschiesche, Eva
Wolf, Oliver
Loehlein, Wolfgang
Pobel, Thierry
Gil, Maria José
Roepke, Rainer K. A.
author_facet Rohdich, Nadja
Zschiesche, Eva
Wolf, Oliver
Loehlein, Wolfgang
Pobel, Thierry
Gil, Maria José
Roepke, Rainer K. A.
author_sort Rohdich, Nadja
collection PubMed
description BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. METHODS: Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment. RESULTS: In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated. CONCLUSIONS: A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
format Online
Article
Text
id pubmed-6240940
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62409402018-11-23 Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats Rohdich, Nadja Zschiesche, Eva Wolf, Oliver Loehlein, Wolfgang Pobel, Thierry Gil, Maria José Roepke, Rainer K. A. Parasit Vectors Research BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. METHODS: Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment. RESULTS: In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated. CONCLUSIONS: A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas. BioMed Central 2018-11-19 /pmc/articles/PMC6240940/ /pubmed/30454052 http://dx.doi.org/10.1186/s13071-018-3175-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Rohdich, Nadja
Zschiesche, Eva
Wolf, Oliver
Loehlein, Wolfgang
Pobel, Thierry
Gil, Maria José
Roepke, Rainer K. A.
Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
title Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
title_full Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
title_fullStr Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
title_full_unstemmed Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
title_short Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
title_sort field effectiveness and safety of fluralaner plus moxidectin (bravecto® plus) against ticks and fleas: a european randomized, blinded, multicenter field study in naturally-infested client-owned cats
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240940/
https://www.ncbi.nlm.nih.gov/pubmed/30454052
http://dx.doi.org/10.1186/s13071-018-3175-z
work_keys_str_mv AT rohdichnadja fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats
AT zschiescheeva fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats
AT wolfoliver fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats
AT loehleinwolfgang fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats
AT pobelthierry fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats
AT gilmariajose fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats
AT roepkerainerka fieldeffectivenessandsafetyoffluralanerplusmoxidectinbravectoplusagainstticksandfleasaeuropeanrandomizedblindedmulticenterfieldstudyinnaturallyinfestedclientownedcats